Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Drug Makers Look To Cancer Biomedicines For New Products

This article was originally published in PharmAsia News

Executive Summary

At least three of Japan's major drug makers are intensifying efforts to do well in the growing market for anti-cancer biopharmaceuticals that feature fewer side-effects than conventional drugs. Shionogi is the latest to join the field, with expectations of beginning by the end of the fiscal year clinical trials for vaccines to prevent bladder cancer. The drugs rely on proteins found only in cancerous cells use to induce an immune-system response. Eisai and Takeda Pharmaceutical also are developing biopharmaceuticals, with Eisai having just begun trials of a drug for colon and lung cancers, and Takeda set to begin selling colon- and rectal-cancer drugs early next year for an MNC, as well as completing trials on drugs of its own. (Click here for more - a subscription may be required

You may also be interested in...



Perrigo Reports Broad Growth, But Investors Sour On Turnaround's Price Tag

Its reported worldwide consumer Q4 net sales increased 12.7%, or 16.4% adjusted for currency exchange rates, product launches and other changes from the prior-year period, to $1.1bn. The s results, though, sent share price plummeting $8.64, more than 14%, to $51.82.

Bayer Consumer Health Recovery Rides Allergy, Dermatology Brand Sales

Q4 sales in OTC allergy/cold segment, which includes the Claritin allergy and Afrin nasal congestion lines, grew 5% adjusted while dermatology sector with Bepanthen and Canesten skin care brands grew 3.8%. Adjusted for the impact of foreign exchange and portfolio changes, thouhg, consumer unit’s full-year sales were flat.

How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls

The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.

UsernamePublicRestriction

Register

SC072373

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel